Summary & Overview
CPT 0233U: Genomic Unity FXN Analysis, PCR-Free Whole Genome Sequencing
CPT code 0233U designates the Genomic Unity® FXN Analysis, a Proprietary Laboratory Analyses (PLA) test that uses PCR-free whole genome sequencing and algorithmic data analysis of blood or saliva to evaluate the frataxin (FXN) gene for variants associated with conditions such as Friedreich’s ataxia. This single-source PLA code matters nationally because it identifies a manufacturer-specific genomic assay that can affect coverage determinations, prior authorization workflows, and claims processing across commercial and public payers.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical purpose and service setting of the test, payor coverage considerations, common billing modifiers, and where to locate additional coding and manufacturer information. The publication summarizes benchmarks and policy-relevant topics affecting PLA-coded genomic tests, such as how single-source codes influence payer medical policy language and billing granularity. Data not available in the input will be noted as such in relevant sections.
Billing Code Overview
CPT code 0233U is a Proprietary Laboratory Analyses (PLA) code reported for the Genomic Unity® FXN Analysis from Variantyx Inc. The test evaluates the frataxin (FXN) gene for variants relevant to conditions such as Friedreich’s ataxia using a blood or saliva specimen.
Service Type: Genetic testing — PCR-free whole genome sequencing (WGS) with algorithmic analysis
Typical Site of Service: Clinical laboratory (specimens collected from blood or saliva; sequencing and analysis performed in a laboratory setting)
Clinical & Coding Specifications
Clinical Context
A 12-year-old patient presents to a pediatric neurology clinic with progressive gait instability, dysarthria, and a family history suggestive of hereditary ataxia. The neurologist orders a targeted genetic test, 0233U (Genomic Unity® FXN Analysis), using a blood or saliva specimen to evaluate the frataxin (FXN) gene for pathogenic variants associated with Friedreich’s ataxia. The sample is collected in clinic or at a certified collection center and sent to the performing laboratory. The laboratory performs PCR-free whole genome sequencing (WGS) with algorithmic analysis focused on the FXN locus and reports detected variants, zygosity, and interpretation including pathogenicity classification and clinical correlation. Results are returned to the ordering clinician, who integrates molecular findings with clinical exam, family history, and ancillary studies (electrophysiology, cardiac evaluation) to confirm diagnosis, guide genetic counseling, cascade testing of family members, and inform management and surveillance recommendations.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Procedure performed, annotation not required by payer | Rarely used; typically included when no specific modifier applies and payer requires a two-character qualifier. |
26 | Professional component | Use when reporting only the professional interpretation component of the test separate from the technical laboratory processing when billing split components is permitted. |
52 | Reduced services | Use if testing was attempted but performed with reduced scope (e.g., limited analysis due to poor sample) and payer allows reduced-service reporting. |
53 | Discontinued procedure | Use if specimen collection or testing was begun but discontinued for documented medical reasons prior to completion. |
62 | Two surgeons | Applicable if two clinicians with distinct roles perform separate billable clinical services related to the testing encounter (rare for lab PLA codes). |
78 | Unplanned return to OR following surgery | Uncommon; include only if a subsequent surgical event necessitates repeat testing tied to the postoperative complication. |
80 | Assistant surgeon | Use when an assistant surgeon provides a billable role in the clinical procedure associated with sample collection under payer policy. |
82 | Assistant surgeon when qualified resident unavailable | As above, when a qualified resident is not available and an assistant surgeon is used. |
AS | Physician assistant, nurse practitioner, or clinical nurse specialist services for assistant-at-surgery | Use when an APP performs assistant-at-surgery services linked to the test-related procedure per payer rules. |
QK | Medical direction of two, three, or four concurrent anesthesia procedures | Rarely applicable; include only when anesthesia direction for concurrent cases impacted the pathway to testing. |
QX | CRNA service with medical direction by physician | As above; rarely applicable to laboratory testing but available if billed with associated anesthesia services. |
QY | Medical direction of one CRNA by an anesthesiologist | See QK/QX notes; included for completeness when anesthesia services are linked. |
TC | Technical component | Use when billing only the laboratory technical processing component separate from interpretation if payer permits split billing. |
TG | Identifies the provider as a government service/clinic performing the service | Use when the performing laboratory or ordering facility is a federal government entity to indicate government provision of the service. |
| Taxonomy Code | Specialty | Notes |
|---|---|---|
| 261QM0800X | Molecular Pathology | Laboratories and pathologists performing or directing genomic testing. |
| 2080P0207X | Pediatric Neurology | Clinicians commonly ordering 0233U for suspected hereditary ataxias in children and adolescents. |
| 207RG0100X | Medical Genetics | Medical geneticists and genetic counselors who interpret results and provide counseling. |
| 207L00000X | Laboratory Director | Clinical laboratory directors overseeing PLA testing operations. |
| 207Q00000X | Clinical Laboratory | Performing laboratories with specialty in genomics and WGS platforms. |
Related Diagnoses
| ICD-10 Code | Description | Clinical Relevance |
|---|---|---|
G11.1 | Early-onset cerebellar ataxia | Common presenting phenotype leading to 0233U FXN testing for suspected Friedreich’s ataxia. |
G11.10 | Friedreich's ataxia, unspecified | Direct diagnostic target of 0233U sequencing of the FXN gene. |
G11.11 | Friedreich's ataxia with cardiomyopathy | Cardiac involvement often assessed when FXN pathogenic variants are detected. |
R26.2 | Difficulty in walking, not elsewhere classified | Symptom prompting genetic evaluation including FXN analysis. |
R47.1 | Dysarthria and anarthria | Neurologic sign associated with spinocerebellar disorders that may lead to FXN testing. |
Related CPT Codes
| CPT Code | Description | Relationship to This Procedure |
|---|---|---|
81479 | Unlisted molecular pathology procedure | Used when no specific CPT exists for a particular molecular test; historically relevant but 0233U is a PLA unique code replacing unlisted usage. |
36415 | Collection of venous blood by venipuncture | Performed immediately prior to 0233U when blood is the specimen source for genomic testing. |
99347 | Home visit for established patient, subsequent | May be used in contexts where sample collection and clinical follow-up occur in the home setting; adjunct to ordering and result review. |
88172 | Cytopathology, collected smears, interpretation by physician | Not directly related but represents ancillary laboratory processing codes; included as an example of lab technical components that might accompany specimen handling in complex workflows. |
G0453 | Ambulatory clinical lab test not otherwise specified (Medicare) | Used in some Medicare billing workflows for lab tests without a national payment rate; may interface with PLA reporting mechanisms depending on payer rules. |